Process of Care for Hepatitis C Infection Is Linked to Treatment Outcome and Virologic Response

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 11, 2012, Pages

  Kanwal, Fasiha ^a,b   Hoang, Tuyen ^b   Chrusciel, Timothy ^a,c   Kramer, Jennifer R ^a   El Serag, Hashem B ^a,b   Dominitz, Jason A ^a   Asch, Steven M ^a,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Chronic liver disease; Indicator; Performance; Quality of care

Indexed keywords

RIBAVIRIN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GENOTYPE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LABORATORY TEST; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SEROLOGY; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD;

EID: 84867663623     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.07.015     Document Type: Article

References (34)

1. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
2. Kim W.R., Brown R.S., Terrault N.A., et al. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002, 36:227-242.
3. Poynard T., Marcellin P., Lee S.S., et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352:1426-1432.
4. Davis G.L., Esteban-Mur R., Rustgi V., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1493-1499.
5. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
6. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
7. Hadziyannis S.J., Sette H., Morgan T.R., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
8. Poynard T., McHutchison J., Manns M., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303-1313.
9. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416. ADVANCE study team.
10. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206. SPRINT-2 investigators.
11. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374. American Association for the Study of Liver Diseases.
12. Seeff L.B., Hoofnagle J.H. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002, 36(Suppl 1):S1-S2.
13. Kanwal F., Schnitzler M.S., Bacon B.R., et al. Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med 2010, 153:231-239.
14. Kramer J.R., Hachem C.Y., Kanwal F., et al. Meeting vaccination quality measures for hepatitis A and B virus in patients with chronic hepatitis C infection. Hepatology 2011, 53:42-52.
15. Butt A.A., Justice A.C., Skanderson M., et al. Rate and predictors of treatment prescription for hepatitis C. Gut 2007, 56:385-389.
16. McGlynn E.A., Asch S.M. Developing a clinical performance measure. Am J Prev Med 1998, 14(Suppl):14-21.
17. Brook R.H., McGlynn E.A., Cleary P.D. Quality of health care. part 2: measuring quality of care. N Engl J Med 1996, 335:966-970.
18. Asch S.M., McGlynn E.A., Hiatt L., et al. Quality of care for hypertension in the United States. BMC Cardiovasc Disord 2005, 5:1.
19. Higashi T., Shekelle P.G., Adams J.L., et al. Quality of care is associated with survival in vulnerable older patients. Ann Intern Med 2005, 143:274-281.
20. Fitch K., Bernstein S.J., Aguilar M.S. The RAND/UCLA appropriateness method user's manual 2001, RAND, California.
21. McGory M.L., Kao K.K., Shekelle P.G., et al. Developing quality indicators for elderly surgical patients. Ann Surg 2009, 250:338-347.
22. Maggard M.A., McGory M.L., Shekelle P.G., et al. Quality indicators in bariatric surgery: improving quality of care. Surg Obes Relat Dis 2006, 2:423-429.
23. Shekelle P.G., MacLean C.H., Morton S.C., et al. Acove quality indicators. Ann Intern Med 2001, 135:653-667.
24. MacLean C.H., Louie R., Leake B., et al. Quality of care for patients with rheumatoid arthritis. JAMA 2000, 284:984-992.
25. Shekelle P.G., Chassin M.R., Park R.E. Assessing the predictive validity of the RAND/UCLA appropriateness method criteria for performing carotid endarterectomy. Int J Technol Assess Health Care 1998, 14:707-727.
26. Kanwal F., Hoang T., Kramer J., et al. Performance of process quality measures in hepatitis C. Am J Gastroenterol 2012, Epub ahead of print.
27. Backus L.I., Gavrilov S., Loomis T.P., et al. Clinical case registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc 2009, 16:775-783.
28. Backus L.I., Boothroyd D.B., Phillips B.R., et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007, 46:37-47.
29. Beste L.A., Ioannou G.N., Larson M.S., et al. Predictors of early treatment discontinuation among patients with genotype 1 hepatitis C and implications for viral eradication. Clin Gastroenterol Hepatol 2010, 8:972-978.
30. Kanwal F., Hoang T., Spiegel B.M., et al. Predictors of treatment in patients with chronic hepatitis C infection-role of patient versus nonpatient factors. Hepatology 2007, 46:1741-1749.
31. Strader D.B., Wright T., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-1171.
32. McHutchison J.G., Manns M., Patel K., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069.
33. Ferenci P., Fried M.W., Shiffman M.L., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kD)/ribavirin. J Hepatol 2005, 43:425-433.
34. Medicare Quality Measurement and Reporting Programs Centers for Medicare and Medicaid Services, Accessed: March 2012. http://www.healthreformgps.org/resources/medicare-quality-measurement-and-reporting-programs/.